poisar

Stock

Denali Therapeutics Inc. DNLI

$22.98-1.84%

Overview

DNLI market data

Price History

DNLI price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.97
Diluted earnings per share over the trailing twelve months.
Beta
1.00
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$12.58 – $27.30
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $3.7K · P/B 2.54 · P/S 10.90.

Company news

10 captured
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36Benzinga · Jul 23, 2026, 6:04 PM
Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35Benzinga · Jul 16, 2026, 11:45 AM
JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price TargetBenzinga · Jul 13, 2026, 11:03 AM
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 MillionGlobenewswire Inc · Jun 18, 2026, 12:15 PM
Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195MBenzinga · Jun 18, 2026, 12:10 PM
8-K filing — Denali Therapeutics Inc. (DNLI)SEC EDGAR · Jun 18, 2026, 12:01 PM
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35Benzinga · May 26, 2026, 2:28 PM
Trading Halt: Halt status updated at 6:25:00 PM ET: Quotation Resumption: News and Resumption TimesBenzinga · May 21, 2026, 10:30 PM
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s DiseaseGlobenewswire Inc · May 21, 2026, 10:15 PM
Biogen And Denali Discontinue BIIB122 Development In Idiopathic Parkinson's Disease After Phase 2b LUMA Trial Misses Primary And Secondary EndpointsBenzinga · May 21, 2026, 10:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock